IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Spectral Diagnosis of Cutaneous Malignancy
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
| Condition | Intervention |
|---|---|
| Skin Cancer | Device: Spectral Diagnosis Probe |
| Study Type: | Observational |
| Study Design: | Observational Model: Case-Control Time Perspective: Prospective |
| Official Title: | Spectral Diagnosis of Cutaneous Malignancy |
- Spectroscopic features of skin lesions in vivo [ Time Frame: Preparing lesion, imaging it, and collecting the light signals should take about 10-15 minutes per lesion. ]
| Estimated Enrollment: | 350 |
| Actual Study Start Date: | April 2007 |
| Estimated Study Completion Date: | April 2019 |
| Estimated Primary Completion Date: | April 2019 (Final data collection date for primary outcome measure) |
| Groups/Cohorts | Assigned Interventions |
|---|---|
|
Spectral-Diagnosis
Method for noninvasive detection of cutaneous malignancies
|
Device: Spectral Diagnosis Probe
The device collects two types of tissue spectra: i) laser-induced fluorescence spectra and ii) white light reflectance spectra. This portable reflectance spectrofluorimeter collects spectra in a fraction of a second. Light collection and delivery are achieved via an optical fiber probe. The optical fiber probe is approximately 1 mm in diameter and 3 m long. The same probe collects light emitted from the tissue and delivers it back to the instrument for spectral analysis.
Other Name: Optical Spectroscopy
|
Detailed Description:
The spectral-diagnosis probe being used in this study uses dim pulses of light to identify features of tissue that may be related to the status of skin cancer. The probe is shaped like a catheter, and it has a camera on the end, which takes pictures of the skin.
If you agree to take part in this study, you will be asked questions about your age, race, smoking status, and the status of any diseases you may have (such as diabetes, connective tissue disease, and infectious disease). It should take about 5 minutes to answer these questions.
The study doctor will then decide which of your lesions are suitable for imaging by the probe. If necessary, any hair on or around the lesion(s) will be shaved or trimmed. The area(s) of skin being imaged will be cleaned with rubbing alcohol.
As part of your exam, the study doctor will use the probe to measure the selected areas of tissue. To perform the spectral-diagnosis measurement, the probe will be gently placed on the surface of your skin. Each selected area of your skin will take about a few seconds to image. The probe will shine different types of light onto the skin, and it will collect the light that reflects from the skin surface. The light signals will be stored so that researchers can look at them. Preparing the lesion, imaging it, and collecting the light signals should take about 10-15 minutes per lesion.
After all of the imaging is over, you will have biopsies performed on the lesions that your study doctor has decided are in need of such treatment as part of your standard care.
After this clinic visit, your participation in the study will be over.
This is an investigational study. The imaging probe is not commercially available or FDA approved. At this time, it is being used in research only. Up to 150 patients will take part in this study. All will be enrolled at M. D. Anderson.
Eligibility| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
Inclusion Criteria:
- Male or Female and over 18 years of age.
- Patients undergoing an examination of their skin
- Patients with a lesion(s) in one of the five categories: basal cell carcinoma, squamous cell carcinoma, pre-cancer lesions, pigmented lesions, and benign lesions
- Patients whose lesion also warrants a biopsy.
- Signed informed consent document.
Exclusion Criteria:
- Patients with absence of skin lesion(s) in one of the five categories.
- Patients whose identified lesion did not need a biopsy.
- Patients who did not sign the informed consent and agree to participate.
Contacts and LocationsPlease refer to this study by its ClinicalTrials.gov identifier: NCT00476905
| United States, Texas | |
| University of Texas MD Anderson Cancer Center | |
| Houston, Texas, United States, 77030 | |
| Principal Investigator: | Michael Migden, MD | M.D. Anderson Cancer Center |
More Information
Additional Information:
| Responsible Party: | M.D. Anderson Cancer Center |
| ClinicalTrials.gov Identifier: | NCT00476905 History of Changes |
| Other Study ID Numbers: |
2006-0856 |
| Study First Received: | May 18, 2007 |
| Last Updated: | May 30, 2017 |
Keywords provided by M.D. Anderson Cancer Center:
|
Basal Cell Carcinoma Squamous Cell Carcinoma Pre-Cancer Lesions Pigmented Lesions |
Benign Lesions Skin Cancer Spectral Diagnosis Optical Spectroscopy |
Additional relevant MeSH terms:
|
Skin Neoplasms Neoplasms by Site Neoplasms Skin Diseases |
ClinicalTrials.gov processed this record on June 22, 2017